Cargando…

Concomitance of oncogenic HPV types, CHEK2 gene mutations, and CYP1B1 gene polymorphism as an increased risk factor for malignancy

INTRODUCTION: Urinary bladder carcinoma ranks the fourth position in malignancy incidence rates in men (6.1%) and the 17th position in women (1.6%). In general, neoplastic diseases should be approached from two perspectives: prevention with implementation of prophylactic measures and early diagnosti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banaszkiewicz, Monika, Constantinou, Maria, Pietrusiński, Michał, Kępczyński, Łukasz, Jędrzejczyk, Adam, Rożniecki, Marek, Marks, Piotr, Kałużewski, Bogdan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Polish Urological Association 2013
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921859/ https://www.ncbi.nlm.nih.gov/pubmed/24578981 http://dx.doi.org/10.5173/ceju.2013.01.art7

Ejemplares similares

The prevalence of CHEK2 and CYP1B1 mutations/polymorphisms in urinary bladder cancer
por: Banaszkiewicz, Monika, et al.
Publicado: (2012)

Artificial neural network in predicting bladder cancer recurrence
por: Borkowska, Edyta, et al.
Publicado: (2012)

Significance of CDKN2A gene A148T variant in patients with bladder cancer
por: Borkowska, Edyta, et al.
Publicado: (2011)

Detection of loss of heterozygosity in patients with urinary bladder carcinoma: neoplastic tissue vs. urine sediment cells
por: Traczyk, Magdalena, et al.
Publicado: (2011)

Polymorphic variants of H-RAS protooncogene and their possible role in bladder cancer etiology
por: Traczyk, Magdalena, et al.
Publicado: (2012)

Molecular subtyping of bladder cancer using Kohonen self-organizing maps
por: Borkowska, Edyta M, et al.
Publicado: (2014)

The Usefulness of Cell-Based and Liquid-Based Urine Tests in Clarifying the Diagnosis and Monitoring the Course of Urothelial Carcinoma. Identification of Novel, Potentially Actionable, RB1 and ERBB2 Somatic Mutations
por: Kałużewski, Tadeusz, et al.
Publicado: (2021)

The A148T variant of CDKN2A gene in bladder cancer
por: Borkowska, E, et al.
Publicado: (2011)

Genomic imbalance in endometrial hyperplasia and cancer
por: Bednarek, Michal, et al.
Publicado: (2015)

The CHEK 2 GENE mutations and the risk of Gastric cancer
por: Teodorczyk, Urszula, et al.
Publicado: (2012)

The role of selected egzo- and endogenic agents on preinitiation process of bladder cancer
por: Iwaniuk, A, et al.
Publicado: (2015)

EORTC risk tables – their usefulness in the assessment of recurrence and progression risk in non–muscle–invasive bladder cancer in Polish patients
por: Borkowska, Edyta M., et al.
Publicado: (2013)

Age of natural menopause onset in BRCA1/2 carriers – systematic review and meta-analysis
por: Kępczyński, Łukasz, et al.
Publicado: (2021)

Report on the Effect of the Implementation of an Early Detection and Prevention of Cancer Program on Families at High Hereditary Risk—Concentrating on Patients Undergoing Genetic Diagnostics and Counseling in Central Poland
por: Kałużewski, Tadeusz, et al.
Publicado: (2023)

Gene Expression Alterations and Molecular Analysis of CHEK1 in Solid Tumors
por: Fadaka, Adewale Oluwaseun, et al.
Publicado: (2020)

Association of genetic variants in ATR-CHEK1 and ATM-CHEK2 pathway genes with risk of colorectal cancer in a Chinese population
por: Wang, Shijia, et al.
Publicado: (2018)

The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study
por: Alorjani, Mohammed, et al.
Publicado: (2023)

Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma
por: Havranek, Ondrej, et al.
Publicado: (2015)

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2021)

Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent
por: Chinyama, Harold A., et al.
Publicado: (2023)

Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility
por: Trubicka, Joanna, et al.
Publicado: (2010)

No evidence for change in expression of TBC1D1 and TBC1D4 genes in cultured human adipocytes stimulated by myokines and adipokines
por: Kępczyński, Łukasz, et al.
Publicado: (2021)

The influence of selenium concentration and variations in selenoprotein genes on the CHEK2-dependent cancers
por: Gupta, Satish, et al.
Publicado: (2015)

An association study between CHEK2 gene mutations and susceptibility to breast cancer
por: Jalilvand, Manizheh, et al.
Publicado: (2017)

Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures
por: Ow, Ghim Siong, et al.
Publicado: (2014)

Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report
por: Agiannitopoulos, Konstantinos, et al.
Publicado: (2019)

Associations of ATR and CHEK1 Single Nucleotide Polymorphisms with Breast Cancer
por: Lin, Wei-Yu, et al.
Publicado: (2013)

miR-146a Enhances the Oncogenicity of Oral Carcinoma by Concomitant Targeting of the IRAK1, TRAF6 and NUMB Genes
por: Hung, Pei-Shi, et al.
Publicado: (2013)

Whole Genome Sequencing Prioritizes CHEK2, EWSR1, and TIAM1 as Possible Predisposition Genes for Familial Non-Medullary Thyroid Cancer
por: Srivastava, Aayushi, et al.
Publicado: (2021)

Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

Low Prevalence of CHEK2 Gene Mutations in Multiethnic Cohorts of Breast Cancer Patients in Malaysia
por: Mohamad, Suriati, et al.
Publicado: (2015)

Is CHEK2 a moderate-risk breast cancer gene or the younger sister of Li-Fraumeni?
por: De Silva, Dilanka L, et al.
Publicado: (2020)

Recurrent Germline Mutations of CHEK2 as a New Susceptibility Gene in Patients with Pheochromocytomas and Paragangliomas
por: Gao, Yinjie, et al.
Publicado: (2021)

Cyclin D1 and CHEK2 polymorphic variants as low risk susceptibility alleles in DTC patients
por: Hryhorowicz, Szymon, et al.
Publicado: (2015)

Genetic polymorphisms in CYP1A1, CYP1B1 and COMT genes in Greenlandic Inuit and Europeans
por: Ghisari, Mandana, et al.
Publicado: (2013)

Germline mutation of CHEK2 in neurofibromatosis 1 and 2: Two case reports
por: Li, Qiang, et al.
Publicado: (2018)

Maternal heterozygous mutation in CHEK1 leads to mitotic arrest in human zygotes
por: Chen, Beili, et al.
Publicado: (2021)

Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk
por: Bethke, Lara, et al.
Publicado: (2007)

CYP1B1 gene: Implications in glaucoma and cancer
por: Alsubait, Arwa, et al.
Publicado: (2020)

Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D
por: Graffeo, R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fgqlhkvcn472ffsr6k6qd7i1uc